Lenire: How Bimodal Neuromodulation Can Soothe Tinnitus Symptoms -14/1
Recently the results of the Lenire® TENT-A1 clinical trial for the treatment of tinnitus were published in Science Translational Medicine. Join Neuromod Devices for a live and interactive webinar covering the breakthrough research. Whether you’re a healthcare professional passionate about treating tinnitus or a patient seeking to understand how bimodal neuromodulation works – this session is for you. Register now at: https://bit.ly/2WGdgO8
Dr. John Coverstone, Clinical Audiologist at Sentient Healthcare will join Dr. Ross O’Neill, CEO at Neuromod Devices, Professor Hubert Lim, Chief Scientific Officer at Neuromod Devices, and Mr. Brendan Conlon Chief Medical Officer at Neuromod Devices and Principal Investigator of the TENT-A1 trial to discuss:
– How Bimodal Neuromodulation was shown to soothe tinnitus symptoms in the majority of participants;
– How the TENT-A1 trial was designed and run;
– What the TENT-A1’s results mean for tinnitus patients and the future of Lenire®.
There’ll be dedicated time for Q&A. Can’t make it to the live session and don’t want to miss out? Register now and we’ll send you the recording after the session.
The webinar will be moderated by Dr. John Coverstone. John A. Coverstone, AuD, is the President and CEO of Sentient Healthcare, an audiology consulting and clinical services business in New Brighton, MN. Dr. Coverstone specializes in clinical and educational audiology services for people with hearing impairment and tinnitus.
Dr. Coverstone has over 30 years of experience in radio broadcasting and podcasting. He is currently the co-host of AudiologyTalk, the original podcast for audiologists, and Conversations in Tinnitus, the official podcast of the American Tinnitus Association (ATA), as well as a regular contributor for ATA’s Tinnitus Today.